Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Belatacept Process E vs Process C in Healthy Subjects
NCT02564497Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Jan 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belatacept in kidney transplant rejection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time and Maximum Observed Serum Concentration. Started Oct 2015; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02564497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564497.